

# Microbial Complicity and Influence on the Prosperity of Alzheimer's Disease

Ashley Hamby<sup>1</sup>

<sup>1</sup> The University of Louisville, Louisville, KY, USA

## BACKGROUND

Alzheimer's Disease (AD) is a progressive neurodegenerative disease generally characterized by loss of memory, disorientation, and mood/behavioral changes. Advanced cases of Alzheimer's Disease may also include difficulty performing basic motor skills such as speaking and ambulating. There are two types of AD that lead to these devastating symptoms. Familial AD has an early onset and is linked to deterministic mutations in amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) genes [16]. On the other hand, sporadic AD has a late onset and is associated to both genetic and environmental causes. Examples of environmental factors include exposure to pollution/asbestos, diet, tobacco usage, and exercise [26]. Both variations of AD involve the formation and prolonged presence of beta-amyloid plaques and neurofibrillary tangles (comprised of hyperphosphorylated tau proteins) that prevent normal neurological functioning; the two formations are key criteria necessary for official diagnosis of the disease [24,41].

AD currently has no means of therapeutic intervention despite extensive molecular research, emphasizing the vast complexity of the disease. As a result, scientists were forced to expand their prospects towards other potential therapeutic targets, taking large interest in the human flora. This review article will focus on evidence published by various researchers that suggests microbial involvement plays a large role in the development and progression of AD.

### *Senile Amyloid Plaques*

APP is responsible for synaptic stability and neuronal protection [9]. Normally, it is processed by the initial cleavage of  $\alpha$ -secretase and followed up by the  $\gamma$ -secretase to form soluble APP $\alpha$  [9]. Theoretically, senile amyloid plaques are formed by accumulation of A $\beta$ 40 and A $\beta$ 42 peptides following aberrant processing of APP by  $\beta$ - and  $\gamma$ -secretases [33]. A $\beta$ 42 specifically is toxic and susceptible to aggregation in comparison to its counterpart, A $\beta$ 40 [27]. Both frequent pathogen colonization and/or failure to remove these peptides via

exocytosis to form soluble oligomers following appropriate use can lead to over-accumulation between the neuronal spaces [35]. This agglomeration leads to the formation of plaques that are responsible for deteriorating high brain tissue through the interception of cell function. Duplications of the protein-coding APP gene can also result in excessive proliferation of APP, leading to A $\beta$  build-up [9].

Conversely, recent research has proposed that A $\beta$  accumulations display antimicrobial properties. In a study comparing A $\beta$  activity against twelve microorganisms, A $\beta$  was reported to thwart further microbial growth [43]. These findings suggest amyloid plaques may be present as a result of defensive responses against pathogen colonization. Further research, however, has not yet been published quantifying healthy versus excessive amounts of the peptide in question. One of the major hypotheses in the development of AD suggests A $\beta$  protein to be the causative agent of Alzheimer's with subsequent hyperphosphorylation of tau proteins leading to cell loss and vascular damage [39].

### *Neurofibrillary Tangles*

Tau, the main component of neurofibrillary tangles, is a protein that normally binds tightly to microtubules within the brain for functional stabilization [40]. Ordinarily, phosphorylated and non-phosphorylated tau proteins are present and regulated by tau kinases and phosphatases [31]. In the AD-inflicted brain, however, this balance is disrupted and the regulatory mechanism is impaired, causing tau to detach from their associated microtubules and attach to other tau proteins instead. This results in the hyperphosphorylation of tau proteins that assemble as tangles [41]. As a consequence, operations like axonal and dendritic transport are disabled.

### *Neuroinflammation*

Cytokines, which are responsible for the regulation of immunity and inflammatory responses, have been found to have significantly elevated concentrations in the AD brain compared to baseline [44]. For this reason, increased neuroinflammation, plaques, and tangles are thought to work in a cyclic manner regarding brain tissue

deterioration. Amyloid plaques, neurofibrillary tangles and prolonged inflammation lead to tissue damage, but neuroinflammation also facilitates further formation of these debilitating structures [44].

Microglial cells are the major cell type regarding immune responses. Upon activation, these cells produce cytokines as a defensive mechanism against pathogen and tissue damage [51]. Unfortunately, microglial cell activity is highly associated with neurotoxicity despite its intentionally helpful function [6]. When repeatedly stimulated, activation of these cells causes loss of ability to phagocytose A $\beta$  with continued output of cytokines [32]. This ultimately leads to A $\beta$  buildup and enhanced inflammation of brain tissue.

## MICROBES

Microbes, in the eye of the general public, receive a bad reputation. In reality, the presence and exposure to an array of microbes can heavily improve the efficiency of the immune system and help regulate bodily functions [45]. The human microbiota is constituted by a collection of millions of diverse microbes. Though this flora is largely populated by bacteria, other organisms like archaea, protozoa, fungi, and viruses are also present. These microbes reside in nearly all regions of the body, but especially large aggregates are found in the gastrointestinal (GI) tract, skin, oral cavity, respiratory tract, and brain.

### *Microbial Gut-Brain Axis*

The gut-brain axis (GBA) is a bidirectional communication system between the central (CNS) and enteric nervous system (ENS) as well as the hypothalamic pituitary adrenal (HPA) axis [10]. The ENS is a division of the autonomic nervous system that detects and maintains the physiological conditions of the GI tract and coordinates intestinal processes like motility, digestion, and barrier defense [17]. The HPA axis acts as the core stress efferent axis and is responsible for coordination of adaptive responses within the organism [10]. Moreover, as part of the limbic system, the HPA axis is involved with memory and emotional response.

It is known that environmental stressors may activate this communication system, but recent research has pinpointed evidence of gut microbiota acting as a signaling component as well [5]. Study results involving examination of communication between the vagal nerve and GI tract have found that gut microbes can indirectly stimulate the ENS via creation of neurotransmitters, short chain fatty acids, and/or bacterial metabolites [7]. These communications may also be introduced through bacteria that induce a similar effect to host hormones. Naturally, since gut microbes hold a large role in the regulation of

the GI environment, it makes sense that dysbiosis may impede fine-tuned processes.

### *Gut Microbiota*

The GI tract is home to over 10<sup>14</sup> microorganisms that aid in metabolic and homeostatic responses such as enzyme synthesis, nutrient absorption, and production of short-chain fatty acids [10]. Though the intestinal flora accumulates during infancy and remains relatively consistent throughout an individual's life, patients with AD showed decreased richness and diversity of microbes in comparison to non-afflicted individuals of the same age [49]. Under this principle, it has been established that obesity has a complex but major role in the residential phyla of the gut. Multiple studies have compared the relationship between BMI and present flora to find that mid-life increases in BMI are correlated with phyla alteration that ultimately leads to greater risk for AD development [3,18]. Interestingly, the same studies discovered that late life increases of BMI protect against the progression of AD [3,18]. A low-power piloted study found Actinobacteria to be most abundant in postmortem AD brain samples, though this must be implemented on a multi-regional level to better understand the universality of this finding [52]. Irritable bowel syndrome (IBS) also has a strong correlation with the development of dementia secondary to hypothesized gut dysbiosis [12]. Both IBS and gastroenteritis (a great risk factor for development of IBS) have shown to be associated with a multitude of parasitic pathogens and their overgrowth.

There are few named GI-involved pathogens specifically connected to AD. In a study involving AD association with infectious burden from viruses and bacteria, *Helicobacter pylori* was one of five pathogens to implement higher levels of serum A $\beta$ 40 and A $\beta$ 42 compared to those uninfected, which interferes with synaptic function [8,19]. It is suggested that *H. pylori*, which is typically responsible for gastritis and peptic ulcers through elevation of pH, also alters cognitive efficiency through neuroinflammation. Another study exploring the effects of *H. pylori* infection found the pathogen to be responsible for hyperphosphorylation of tau proteins which are fundamental for neurofibrillary tangles as mentioned before [50].

Though the causative role of dysbiosis needs further workup, evaluating the effects of antimicrobial properties have supported the idea of pathogen-influenced physiological changes. In a study of transgenic AD mice raised under germ-free conditions, less cerebral amyloid depositions were present in comparison to mice exposed to germs [21]. Intriguingly, antibiotic treatment has shown to be associated with a decrease in fibril formation and an increase in cognitive function [46]. It is important to note that antibiotics vary in terms of ability to cross the

blood brain barrier (BBB) [34]. Rifampicin, a compound with penetrative potential, has shown a decrease in A $\beta$  toxicity and aggregation. A study involving mice has also shown broad-spectrum antibiotics to decrease tau phosphorylation [47]. Despite these findings, absence of microbiota did not equate to complete elimination of plaque development.

### *Oral Microbiota*

Roughly 700 different microorganisms colonize the mouth to make up the oral microbiota [25]. While these microbes are responsible for medical issues such as dental caries, periodontal disease, and edentulism, they also have a strong association with AD [36]. Attachment of microcolonies in the form of biofilms, commonly known as dental plaques, can result in increased virulence of pathogens if not removed by taking practice in proper oral hygiene [28]. Unless gingival ulcers are present, the routine brushing of teeth poses little to no risk for bacteremia to travel through the blood stream and colonize the heart and brain [4,22].

Pathogens that lead to periodontitis may colonize the oral cavity and form toxins that decay the teeth and nearby tissue, which further increase the probability of spread [23,42]. *Porphyromonas gingivalis* is considered one of the major infectious agents found in the brain of AD patients [15]. In patients with active chronic periodontitis (CP) caused by *P. gingivalis*, a notable decline in cognition was reported in comparison to those demented without CP [23]. With a study involving *Apoe*<sup>-/-</sup> mice, three different bacterial oral infections were induced [38]. Only those infected by *P. gingivalis* showed infection of the brain and activation of complement pathways. A similar study with transgenic mice that overexpressed mutated human-APP were orally infected by *P. gingivalis*. Upon examination of their brains, cognitive function was deemed impaired and there arose an increase in deposition of plaques similar to those in AD patients [42]. Gingipains, the major virulence factor produced by *P. gingivalis*, are cysteine proteases made up of lysine-gingipain (Kgp), arginine-gingipain A (RgpA) and arginine-gingipain B (RgpB) [30]. Gingipains are responsible for inflammatory cascades that lead to the brain as they suppress interleukin-2 (IL-2) secretion, which is an extremely important humoral immune response to invasion [37]. This modifies the clonal formation of T helper 17 (Th17) cells, resulting in an immune cell population imbalance that works in favor of *P. gingivalis*. These cysteine proteases may induce proteolysis of tau proteins to which the host attempts to compensate for, increasing production rates to maintain homeostasis [40]. *P. gingivalis* may access the brain upon oral infection through several pathways, including monocytes, endothelial cells pertaining to the BBB, and/or cranial

nerves [15]. Upon entering the brain, it is suggested that the bacteria is spread via the same mechanism through which it invades vascular tissue: it travels through connected pathways to reach an abundance of neurons [42].

*P. gingivalis* infection can work in conjunction with genetic factors that pose increased risk of AD development, such as apolipoprotein E4 (APOE4) and triggering receptors expressed on myeloid cells (TREM1/TREM2). With APOE4, the apolipoprotein itself is a large target for gingipain proteolysis which may result in the generation of neurotoxic fragments [30]. TREM2, which normally regulates inflammatory responses, serves as a phagocytic receptor for bacteria [16]. TREM1, with structural homology to TREM2, has also been linked with AD as *P. gingivalis* has proved to increase expression of the allele that is already a target for gingipain proteolysis (by Rgp) and degradation (by Kgp) [16]. These actions have a correlation with neuroinflammation following infection.

A study evaluating herpes virus simplex 1 (HSV 1) was also linked to increased risk for the development of AD. Multiple logistic regressions found that APOE4 frequency was much higher in those affected by both HSV1 and AD, signifying a strong risk factor when paired [8]. Though recurrence of HSV1 symptoms lessen with age, the connection between the virus and APOE4 may determine the extent of damage. Both the virus and apolipoproteins bind to heparin sulphate proteoglycans in cell plasma membranes which affects the number of cells infected. The mechanism of HSV1 as a vector, however, must be further investigated.

### *Respiratory Microbiota*

The respiratory tract, with lower components previously thought to be sterile, actually harbors a large array of microorganisms that aid in resistance of pathogen colonization [13,14]. Acutely responsible for community-acquired pneumonia and asthmatic bronchitis, recent studies have pinpointed *Chlamydia pneumoniae* infection as a potential trigger for AD. Mice inoculated with *C. pneumoniae* demonstrated A $\beta$ 42 deposits that steadily increased in number over the course of 1-3 months [29]. This microorganism has demonstrated elicitation of extreme inflammatory responses, which are characteristic in the AD brain [20]. With higher bacterial burden showed extremely high levels of tissue and cellular damage within the brains of AD patients. Data also suggests the load has a positive correlation with the presence of the APOE4 allele, though the role in neuropathogenesis is unclear [20].



## *Mycobiota*

The term “mycobiota” refers to fungal microbial flora, which makes up less than 1% of the human flora entirely [48]. Fungi is most typically found either on the skin or within the mucosal membranes of the human body. However, recent examination of brain tissue has unveiled the presence of fungal DNA and proteins in patients with AD [2] as well as fungal residues within neurons [37], all of which were not observed in control patients. Cerebrospinal fluid (CSF) may tell a lot about fungal contribution to AD. Within the CSF of those positive for Alzheimer’s, chitin (the major component of fungal cell walls) has been identified [11].

*Candida albicans* is one of the major fungal organisms found in CSF. Candidemia, caused by *C. albicans*, proves the ability of fungi to cross the BBB. Recent studies have shown *C. albicans* to increase activation of both interleukins and tumor necrosis factors, indicating the fungi can cause extensive neuroinflammation upon seepage into the BBB [51]. The presence of the fungus within the BBB additionally leads to enhancement of the development of A $\beta$  plaques due to their antimicrobial properties [43,51]. It is therefore plausible that formation occurs as a defensive response against *C. albicans*. Another cytoplasmic experiment has found AD brain tissue to have abnormally high amounts of tau when fungal infection has come into the equation, though this finding has not been verified through separate studies [37].

## CONCLUSION

Though microbes are not considered to be the sole drivers in development and progress, there is paramount evidence supporting the association between dysbiosis and AD. Further research in attempt to understand exact mechanisms of pathogenesis and roles of individual microorganisms is imperative if there is any hope for a treatment or cure for AD. Although fungi has remarkable associations with AD, significance of the results are limited due to low quantity of animal studies. This is especially important considering the conceptual confliction with the amyloid cascade hypothesis.

It is known that genes like TREM1, TREM2, and especially APOE4 have a major part in the development of amyloid plaques and neurofibrillary tangles. It would appear that the presence of the APOE4 allele supports or promotes pathogenesis of several harmful microbes [20]. These genetic risks impose facilitation of pathogens through the BBB where they may induce neuroinflammation and/or development of neurologically debilitating structures.

With the aforementioned findings, there are many implications. For example, it is in the best interest of

everyone, especially those with a higher predisposition to AD, to finish the dosed course of antibiotic treatment in wake of infection to minimize the risk of bacterial allocation and/or resistance. Oral hygiene may also be a pertinent step in prevention of oral-associated interactions that lead to progression of AD. Among the gut microbiome, weight maintenance and diet also have emphasized importance in regulation of the flora and associations with AD there. The consumption of probiotics may aid in this process to cancel dysbiosis [1]. While genetic changes may not be plausible, being proactively well-rounded in maintenance of one’s health is thought to be a supportive factor in keeping distance from AD.

## REFERENCES

1. Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., and Tamtaji, O.R. 2016. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. *Frontiers in Aging Neuroscience*. 8: 256.
2. Alonso, R., Pisa, D., Marina, A.I., Morato, E., Rábano, A., and Carrasco, L. 2014. Fungal Infection in Patients with Alzheimer’s Disease. *Journal of Alzheimer’s Disease*. 41: 301-311.
3. Antsey, K.J., Cherbuin, N., Budge, M., and Young, J. 2011. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. *Obesity Reviews*. 12: 426-437.
4. Arweiler, N.B. and Netuschil, L. 2016. The Oral Microbiota. *Advances in Experimental Medicine and Biology*. 902: 45-60.
5. Bercik, P., Collins, S.M., and Verdu E.F. 2012. Microbes and the gut-brain axis. *Neurogastroenterology & Motility*. 24: 405-413.
6. Block, M.L., Zecca, L., and Hong, J. 2007. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. *Nature Reviews Neuroscience*. 8: 57-69.
7. Bohorquez, D.V., Shahid, R.A., Erdmann, A., Kreger, A.M., Wang, Y., and Calakos, N. 2015. Neuroepithelial circuit formed by innervation of sensory enteroendocrine cells. *The Journal of Clinical Investigation*. 125: 782-786.
8. Bu, X.L., Yao, X.Q., Jiao, S.S., Zeng, F., Liu, Y.H., Xiang, Y., Liang, C.R., Wang, Q.H., Wang, X., Cao, H.Y., Yi, X., Deng, B., Liu, C.H., Xu, J., Zhou, H.D., and Wang, Y.J. 2015. A study on the association between infectious burden and Alzheimer’s disease. *European Journal of Neurology*. 22: 1519-1525.
9. Bulgart, H.R., Neczypor, E.W., Wold, L.E., and Mackos, A.R. 2020. Microbial involvement in Alzheimer’s disease development and progression.
10. Carabotti, M., Scirocco, A., Maselli, M.A., and Severi, C. 2015. The gut-brain axis: interactions between the enteric microbiota, central and enteric nervous systems. *Annals of Gastroenterology*. 28: 203-209.
11. Castellani, R.J., Siedlak, S.L., Fortino, A.E., Perry, G., Ghetti, B., and Smith, M.A. 2005. Chitin-like polysaccharides in Alzheimer’s disease brains. *Current Alzheimer’s Research*. 2: 419-423.
12. Chen, C.H., Lin, C.L., and Kao, C.H. 2016. Irritable bowel syndrome is associated with increased risk of dementia: a nationwide population-based study. *PLoS One*. 11: e0144589.
13. De Steenhuijsen Pijters, W.A.A., Sanders, E.A.M., and Bogaert, D. 2015. The role of the local microbial ecosystem in respiratory health and disease. *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences*. 370: 20140294.

14. Dickson, R.P., Erb-Downward, J.R., Martinez, F.J., and Huffnagle, G.B. 2015. The Microbiome and the Respiratory Tract. *Annual Review of Physiology*. 78: 481-504.
15. Dominy, S.S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nyugen, M., Haditsch, U., Raha, D., Griffin, C., Holsinger, L.J., Arastu-Kapur, S., Kaba, S., Lee, A., Ryder, M.I., Potempa, B., Mydel, P., Hellvard, A., Adamowicz, K., Hasturk, H., Walker, G.D., Reynolds, E.C., Faull, R.L.M., Curtis, M.A., Dragunow, M., and Potempa, J. 2019. *Porphyromonas gingivalis* in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. *Science Advances*. 5: eaau3333.
16. Dorszewska, J., Prendecki, M., Oczkowska, A., Dezor, M., and Kozubski, W. 2016. Molecular Basis of Familial and Sporadic Alzheimer's Disease. *Current Alzheimer Research*. 13: 952-963.
17. Drokhylyansky, E., Smillie, C.S., Van Wittenberghe, N., Ericsson, M., Griffin, G.K., Eraslan, G., Dionne, D., Cuoco, M.S., Goder-Reiser, M.N., Sharova, T., Kuksenko, O., Aguirre, A.J., Boland, G.M., Graham, D., Rozenblatt-Rosen, O., Xavier, R.J., and Regev, A. 2020. The Human and Mouse Enteric Nervous System at Single-Cell Resolution. *Cell*. 182: 1606-1622.
18. Fitzpatrick, A.L., Kuller, L.H., Lopez, O.L., Diehr, P., O'Meara, E.S., and Longstreth, W.T Jr. 2009. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. *Archives of Neurology*. 66: 336-342.
19. Franceschi, F., Ojetti, V., Candelli, M., Covino, M., Cardone, S., Potenza, A., Simeoni, B., Gabrielli, M., Sabia, L., Gasbarrini, G., Lopetuso, L., Scaldaferrri, F., Rossini, P.M., and Gasbarrini, A. 2019. Microbes an Alzheimer' disease: lessons from H. pylori and GUT microbiota. *European Review for Medical and Pharmacological Sciences*. 23: 426-430.
20. Gérard, H.C., Wildt, K.L., Whittum-Hudson, J.A., Lai, Z., Ager, J., and Hudson, A.P. 2005. The load of *Chlamydia pneumoniae* in the Alzheimer's brain varies with APOE genotype. *Microbial Pathogenesis*. 39: 19-26.
21. Harach, T., Marunguang, N., Duthilleul, N., Cheatham, V., McCoy, K.D., Frisoni, G., Neher, J.J., Fåk, F., Jucker, M., Lasser, T., and Bolmont, T. 2017. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. *Scientific Reports*. 7: 41802.
22. Hartzell, J.D., Torres, D., Kim, P., and Wortmann, G. 2005. Incidence of bacteremia after routine tooth brushing. *The American Journal of the Medical Sciences*. 329: 178-180.
23. Ide, M., Harris, M., Stevens, A., Sussams, R., Hopkins, V., Culliford, D., Fuller, J., Ibbett, P., Raybould, R., Thomas, R., Puenter, U., Teeling, J., Perry, V.H., and Holmes, C. 2016. Periodontitis and cognitive decline in Alzheimer's disease. *PLOS One*. 11: e0151081.
24. Jagust, W. 2016. Is amyloid- $\beta$  harmful to the brain? Insights from human imaging studies. *Brain*. 139: 23-30.
25. Kilian, M., Chapple, I.L.C., Hannig, M., Marsh, P.D., Pedersen, A.M.L., Tonetti, M.S., Wade, W.G., and Zaura, E. 2016. The oral microbiome – an update for the oral healthcare professionals. *British Dental Journal*. 221: 657-666.
26. Killin, L.O., Starr, J.M., Shiue, I.J., and Russ, T.C. 2016. Environmental risk factors for dementia: a systematic review. *BMC Geriatrics*. 16: 175.
27. Klein, A.M., Kowall, N.W., and Ferrante, R.J. 1999. Neurotoxicity and oxidative damage of beta amyloid 1-42 versus beta amyloid 1-40 in the mouse cerebral cortex. *Annals of the New York Academy of Sciences*. 893: 314-320.
28. Koo, H., Xiao, J., and Klein, M.I. 2009. Extracellular Polysaccharides Matrix – An Often Forgotten Virulence Factor in Oral Biofilm Research. *International Journal of Oral Science*. 1: 229-234.
29. Little, C.S., Hammond, C.J., MacIntyre, A., Balin, B.J., and Appelt, D.M. 2004. *Chlamydia pneumoniae* induces Alzheimer-like amyloid plaques in brains of BALB/c mice. *Neurobiology of Aging*. 25: 419-429.
30. Lönn, J., Ljunggren, S., Klarström-Engström, K., Demirel, I., Bengtsson, T., and Karlsson, H. 2018. Lipoprotein modifications by gingipains of *Porphyromonas gingivalis*. *Journal of Periodontal Research*. 53: 403-413.
31. Martin, L., Latypova, X., Wilson, C., Magnaudeix, A., Perrin, M.L., and Yardin, C. 2013. Tau protein kinases; involve in Alzheimer's disease. *Ageing Research Reviews*. 2: 289-309.
32. Mosher, K.I. and Wyss-Coray, T. 2014. Microglial dysfunction in the brain aging and Alzheimer's disease. *Biochemical Pharmacology*. 88: 594-604.
33. Murphy, M.P. and LeVine, H. 2010. Alzheimer's Disease and the  $\beta$ -Amyloid Peptide. *Journal of Alzheimer's Disease*. 19: 311-323.
34. Nau, R., Sörgel, F., and Eiffert, H. 2010. Penetration of drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections. *Clinical Microbiology Reviews*. 23: 858-883.
35. O'Brien, R.J. and Wong, P.C. 2011. Amyloid precursor protein processing in Alzheimer's disease. *Annual Review of Neuroscience*. 34: 185-204.
36. Olsen, L., Taubman, M.A., and Singhrao, S.K. 2016. *Porphyromonas gingivalis* suppresses adaptive immunity in periodontitis, atherosclerosis, and Alzheimer's disease. *Journal of Oral Microbiology*. 8: 33029.
37. Pisa, D., Alonso, R., Rábano, A., Rodal, I., and Carrasco, L. 2015. Different Brain Regions are Infected with Fungi in Alzheimer's Disease. *Scientific Reports*. 5: 15015.
38. Poole, S., Singhrao, S.K., Kesavalu, L., Curtis, M.A., and Crean, S. 2015. Active invasion of *porphyromonas gingivalis* and infection-induced complement activation in ApoE<sup>-/-</sup> mice brains. *Journal of Alzheimer's Disease*. 43: 67-80.
39. Ricciarelli, R. and Fedele, E. 2017. The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind. *Current Neuropharmacology*. 15: 926-935.
40. Sato, C., Barthélemy, N.R., Mawuenyega, K.G., Patterson, B.W., Gordon, B.A., Jockel-Balsarotti, J., Sullivan, M., Crisp, J., Kasten, T., Kirmess, K.M., Kanaan, N.M., Yarasheski, K.E., Baker-Nigh, A., Bezinger, T.L.S., Miller, T.M., Karch, C.M., and Bateman, R.J. 2018. Tau kinetics in neurons and the human central nervous system. *Neuron*. 97: 1284-1298.
41. Selkoe, D.J. 2001. Alzheimer's Disease: Genes, Proteins, and Therapy. *The American Physiological Society*. 81: 741-766.
42. Singhrao, S.L., Harding, A., Poole, S., Kesavalu, L., and Crean, S. 2015. *Porphyromonas gingivalis* periodontal infection and its putative links with Alzheimer's disease. *Mediators of Inflammation*. 2015: 137357.
43. Soscia, S.J., Kirby, J.E., Washicosky, K.J., Tucker, S.M., Ingelsson, M., Hyman, B., Burton, M.A., Goldstein, L.E., Duong, S., Tanzi, R.E., and Moir, R.D. 2010. The Alzheimer's Disease-Associated Amyloid  $\beta$ -Protein Is an Antimicrobial Peptide. *PLOS One*. 5: e9505.
44. Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., and Herrmann, N. 2010. A meta-analysis of cytokines in Alzheimer's disease. *Biological Psychiatry*. 68: 930-941.
45. Thomas, S., Izard, J., Walsh, E., Batich, K., Chongsathidkiet, P., Clarke, G., Sela, D.A., Muller, A.J., Mullin, J.M., Albert, K., Gilligan, J.P., DiGiuliu, K., Dilbarova, R., Alexnader, W., and Prendergast, G.C. 2017. The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. *Cancer Research*. 77: 1783-1812.
46. Tomiyama, T., Asano, S., Suwa, Y., Morita, T., Kataoka, K., and Mori, H. 1994. Rifampicin prevents the aggregation and neurotoxicity of amyloid  $\beta$  protein in vitro. *Biochemical and Biophysical Research Communications*. 204: 76-83.
47. Tomiyama, T., Shoji, A., Kataoka, K., Suwa, Y., Asano, S., and Kaneko, H. 1996. Inhibition of amyloid beta protein aggregation

- and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. *The Journal of Biological Chemistry*. 271: 6839-6844.
48. Underhill, D.M. and Iliev, I.D. 2015. The mycobiota: interactions between commensal fungi and the host immune system. *Nature Reviews Immunology*. 14: 405-416.
49. Vogt, N.M., Kerby, R.L., Dill-McFarland, K.A., Harding, S.J., Merluzzi, A.P., Johnson, S.C., Carlsson, C.M., Asthana, S., Zetterberg, H., Blennow, K., Bendlin, B.B., and Rey, F.E. 2017. Gut microbiome alterations in Alzheimer's disease. *Scientific Reports*. 7: 13537.
50. Wang, X.L., Zeng, J., Yang, Y., Xiong, Y., Zhang, Z.H., Qiu, M., Yan, X., Sun, X.Y., Tuo, Q.Z., Liu, R., and Wang, J.Z. 2015. *Helicobacter pylori* filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3 $\beta$ . *Journal of Alzheimer's Disease*. 43: 153-165.
51. Wu, Y., Du, S., Johnson, J.L., Tung, H.Y., Landers, C.T., and Liu, Y. 2019. Microglia and amyloid precursor protein coordinate control of transient *Candida cerebritis* with memory deficits. *Nature Communications*. 10: 58.
52. Emery, D.C., Shoemark, D.K., Batstone, T.E., Waterfall, C.M., Coghil, J.A., Cerajewska, T.L., Davies, M., West, N.X., and Allen, S.J. 2017. 16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer's Post-Mortem Brain. *Frontier in Aging Neuroscience*. 9: 195.
-